Today: 11 June 2026
Citigroup stock today: Citi shares rise as yields climb, with jobs data and earnings next on deck
3 January 2026
1 min read

Citigroup stock today: Citi shares rise as yields climb, with jobs data and earnings next on deck

NEW YORK, Jan 3, 2026, 2:51 PM ET — Market closed

Citigroup shares rose 1.7% on Friday to close at $118.70, a first-session lift for 2026 that tracked a rise in U.S. Treasury yields. The benchmark S&P 500 ended up 0.19% as the 10-year yield climbed to 4.191%.

The move matters because big banks tend to trade on interest-rate expectations. When longer-term yields rise, it can support net interest income — the spread between what a bank earns on loans and pays on deposits — though higher rates can also raise funding costs.

It also lands at a time when investors are trying to reset positioning for early-January data and the start of quarterly bank results, both of which can shift views on the pace of Federal Reserve rate cuts and the outlook for credit.

Citi traded between $116.59 and $118.72 in Friday’s session, and it remains within a 52-week range of $55.51 to $122.84. At Friday’s close, the stock sat roughly 3% below that 52-week high.

Other money-center banks also advanced on the day. Wells Fargo rose 2.1%, Bank of America added 1.7% and JPMorgan gained 1.0%.

Citi has also been in focus heading into earnings after it confirmed it had obtained internal approvals to proceed with a planned sale of AO Citibank, its remaining operations in Russia, to Renaissance Capital. Citi said the approvals result in a fourth-quarter 2025 pre-tax loss on sale largely tied to a currency translation adjustment — an accounting effect from converting foreign-currency results into dollars — and that the cumulative impact would be capital neutral to its CET1 ratio, a key measure of bank capital strength.

Before Monday’s open, traders will be watching a busy U.S. calendar that includes the monthly employment report due Jan. 9 and the consumer price index due Jan. 13, Reuters reported. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak. Reuters

Citi’s next scheduled catalyst is its fourth-quarter 2025 results. The bank has said it plans to issue the release at about 8 a.m. ET on Jan. 14 and review results via webcast and teleconference at about 11 a.m. ET.

In that report, investors will be watching net interest trends, credit quality and expense control. Any update on the Russia exit timeline and how the accounting loss flows through capital metrics could also draw attention.

Traders will also focus on technical levels after Friday’s bounce. Near-term support sits around Friday’s low near $116.50, while resistance is clustered near the 52-week high area around $123.

With U.S. markets shut for the weekend, Citi shares are likely to take their next cue from Treasury yields, rate-cut expectations and the tone of early bank-earnings commentary when trading resumes Monday.

Stock Market Today

  • How to Invest Indirectly in SpaceX Before IPO Through ETFs
    June 11, 2026, 10:46 AM EDT. Investors can gain indirect exposure to SpaceX ahead of its IPO via ETFs like ERShares Private-Public Crossover ETF (XOVR) and AGIX. These funds use special purpose vehicles (SPVs)-legal entities holding SpaceX shares-to navigate SEC rules allowing up to 15% allocation in illiquid private companies. XOVR holds about 13.2% exposure to SpaceX through SPVs, while AGIX combines SPV investments with a small direct stake. Investors should note these ETFs are thematic portfolios with broad tech focuses and relatively high expense ratios. Direct public investment remains available only after SpaceX's Nasdaq debut at ticker SPCX on June 12, priced around $135, targeting a $1.75-$2 trillion valuation.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Quantum computing stocks surge to start 2026: D-Wave, Rigetti, IonQ lead — what investors watch next
Previous Story

Quantum computing stocks surge to start 2026: D-Wave, Rigetti, IonQ lead — what investors watch next

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom
Next Story

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Go toTop